Table 1 Results of univariate analyses in liver cancer

From: Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma

Variables

No. of pat.

OS

No. of event

MST

Χ 2

P

Gender

 M

57

38

34.379

1.362

0.243

 F

18

13

49.279

HBV

 Yes

47

31

50.225

0.955

0.328

 No

28

20

37.103

AFP

 Normal

41

27

46.332

0.167

0.683

 Elevated

28

21

43.324

 NA

CA199

 Normal

38

24

49.987

8.404

0.004

 Elevated

23

20

25.283

 NA

Histology

 HCC

32

20

61.16

39.516

0.009

 ICC

28

21

32.858

 CHC

15

10

29.038

Size

 <5 cm

43

29

51.091

1.095

0.295

 >5 cm

32

22

40.582

Number

 1

52

32

51.091

1.095

0.295

 >2

23

19

37.885

Differentation

 High

11

5

65.519

2.642

0.104

 Low/modreate

53

38

44.269

Vascular invasion

 Yes

9

7

36.820

0.778

0.378

 No

66

44

46.773

  

Margin

 Positive

15

13

51.995

7.732

0.005

 Negative

60

38

23.267

  

TACE

 Yes

44

31

45.507

0.073

0.788

 No

31

20

47.191

  

Hepatocyte

 Positive

39

25

54.548

3.711

0.054

 Negative

36

26

35.337

  

GPC3

 Positive

32

23

45.197

0.104

0.747

 Negative

43

28

47.373

  

Hepatocyte/GPC3

 Positive

47

30

52.426

2.918

0.088

 Negative

28

21

34.572

  

CK7

 Positive

43

29

39.425

2.3

0.129

 Negative

22

22

54.523

  

CK19

 Positive

42

28

35.361

4.698

0.030

 Negative

33

23

56.665

  

CK7/CK19

 Positive

49

33

39.721

2.670

0.102

 Negative

26

18

56.772

  

EpCAM

 Positive

39

24

36.206

4.841

0.028

 Negative

36

27

56.132

  
  1. No. of pat. number of patient; OS, overall survival; MST, mean survival time; TACE, transcatheter arterial chemoembolization
Back to article page